BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haidar G, Mellors JW. Improving the Outcomes of Immunocompromised Patients with COVID-19. Clin Infect Dis 2021:ciab397. [PMID: 33949644 DOI: 10.1093/cid/ciab397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Agha ME, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. Open Forum Infect Dis 2021;8:ofab353. [PMID: 34337100 DOI: 10.1093/ofid/ofab353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nair S, Chen X. Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: A systematic review of evidence to support global policy-level actions and research. Glob Health J 2021. [PMID: 34840854 DOI: 10.1016/j.glohj.2021.11.005] [Reference Citation Analysis]
3 Lodi L, Moriondo M, Pucci A, Pisano L, Ricci S, Indolfi G, Azzari C. Chronic asymptomatic SARS-CoV-2 infection in the immunocompromised patient: new challenges and urgent needs. Clin Infect Dis 2021:ciab538. [PMID: 34157075 DOI: 10.1093/cid/ciab538] [Reference Citation Analysis]
4 Di Fusco M, Lin J, Vaghela S, Lingohr-Smith M, Nguyen JL, Scassellati Sforzolini T, Judy J, Cane A, Moran MM. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines 2022;:1-17. [PMID: 35112973 DOI: 10.1080/14760584.2022.2035222] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Montejano R, Marcelo C, Falces-Romero I, Del Valle LG, De Soto T, Garcia-Rodríguez J, Arribas JR. Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV. AIDS 2022;36:751-3. [PMID: 35323160 DOI: 10.1097/QAD.0000000000003179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Haase M, Lesny P, Anderson M, Cloherty G, Stec M, Haase-Fielitz A, Haarhaus M, Santos-Araújo C, Veiga PM, Macario F. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study. J Nephrol 2022. [PMID: 35084719 DOI: 10.1007/s40620-022-01247-7] [Reference Citation Analysis]
7 Rosolanka R, Henao-Martinez AF, Pisney L, Franco-Paredes C, Krsak M. COVID-19: a review of current knowledge regarding exposure, quarantine, isolation and other preventive measures. Ther Adv Infect Dis 2021;8:20499361211032039. [PMID: 34349986 DOI: 10.1177/20499361211032039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Di Fusco M, Moran MM, Cane A, Curcio D, Khan F, Malhotra D, Surinach A, Miles A, Swerdlow D, McLaughlin JM, Nguyen JL. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Econ 2021;24:1248-60. [PMID: 34844493 DOI: 10.1080/13696998.2021.2002063] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Elliott EI, Wang A. Interferon gamma runs interference on persistent COVID-19. Med (N Y) 2021;2:1111-3. [PMID: 34661183 DOI: 10.1016/j.medj.2021.09.004] [Reference Citation Analysis]
10 Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, Morrocchi E, Colagrossi L, Russo C, Zaffina S, Di Matteo G, Cifaldi C, Di Cesare S, Rivalta B, Pacillo L, Santilli V, Giancotta C, Manno EC, Ciofi Degli Atti M, Raponi M, Rossi P, Finocchi A, Cancrini C, Perno CF, Moschese V, Palma P. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. Front Immunol 2021;12:727850. [PMID: 34671350 DOI: 10.3389/fimmu.2021.727850] [Reference Citation Analysis]